Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.65)
# 186
Out of 5,118 analysts
141
Total ratings
52.42%
Success rate
42.88%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Buy | $9 | $2.02 | +345.54% | 1 | Dec 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $25.33 | +65.81% | 2 | Dec 1, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $30 → $40 | $26.87 | +48.86% | 2 | Nov 21, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $12 | $9.40 | +27.66% | 1 | Nov 19, 2025 | |
| NVAX Novavax | Reiterates: Buy | $18 → $16 | $6.83 | +134.26% | 20 | Nov 10, 2025 | |
| CYTK Cytokinetics | Reiterates: Buy | $80 → $90 | $63.11 | +42.61% | 5 | Nov 10, 2025 | |
| HROW Harrow | Reiterates: Buy | $70 → $74 | $50.09 | +47.73% | 4 | Oct 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $460 → $560 | $598.91 | -6.50% | 13 | Sep 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $85 → $105 | $44.49 | +136.01% | 3 | Sep 23, 2025 | |
| TGTX TG Therapeutics | Maintains: Buy | $53 → $55 | $30.77 | +78.75% | 14 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $18.84 | +48.62% | 1 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.47 | +209.36% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $3.86 | +366.32% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.27 | +293.70% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $1.61 | +86.34% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.35 | +478.03% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $12.85 | +55.64% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.65 | +81.82% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $16.87 | +107.47% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $70.16 | -45.84% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $37.18 | +158.20% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.45 | +3.45% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $14.10 | +892.91% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $4.50 | +1,900.00% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.31 | +4,733.84% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $3.15 | +58.73% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.18 | +1,918.35% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $3.74 | +2,306.42% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.73 | +304.62% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.02 | +441,076.47% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.21 | +223,040.50% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $6.16 | +1,150.00% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $0.87 | +166,354.75% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $4.05 | -1.23% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $97.13 | -59.85% | 2 | Mar 18, 2020 |
Opus Genetics
Dec 10, 2025
Initiates: Buy
Price Target: $9
Current: $2.02
Upside: +345.54%
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $25.33
Upside: +65.81%
Zymeworks
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $26.87
Upside: +48.86%
Nuvation Bio
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $9.40
Upside: +27.66%
Novavax
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $6.83
Upside: +134.26%
Cytokinetics
Nov 10, 2025
Reiterates: Buy
Price Target: $80 → $90
Current: $63.11
Upside: +42.61%
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $50.09
Upside: +47.73%
Madrigal Pharmaceuticals
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $598.91
Upside: -6.50%
Nektar Therapeutics
Sep 23, 2025
Maintains: Buy
Price Target: $85 → $105
Current: $44.49
Upside: +136.01%
TG Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $30.77
Upside: +78.75%
Sep 12, 2025
Initiates: Buy
Price Target: $28
Current: $18.84
Upside: +48.62%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $6.47
Upside: +209.36%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $3.86
Upside: +366.32%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.27
Upside: +293.70%
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.61
Upside: +86.34%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.35
Upside: +478.03%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $12.85
Upside: +55.64%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.65
Upside: +81.82%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $16.87
Upside: +107.47%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $70.16
Upside: -45.84%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $37.18
Upside: +158.20%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.45
Upside: +3.45%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $14.10
Upside: +892.91%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $4.50
Upside: +1,900.00%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.31
Upside: +4,733.84%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $3.15
Upside: +58.73%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.18
Upside: +1,918.35%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $3.74
Upside: +2,306.42%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.73
Upside: +304.62%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.02
Upside: +441,076.47%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.21
Upside: +223,040.50%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $6.16
Upside: +1,150.00%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $0.87
Upside: +166,354.75%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $4.05
Upside: -1.23%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $97.13
Upside: -59.85%